Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.
Adapted from Loibl S, et al. 2016.2
Data cut-off date: March 16, 2015.
*Evaluated according to RECIST Version 1.1.3 †Pre-/peri-menopausal patients enrolled in PALOMA-3 received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of the trial.2
CI = confidence interval; FUL = fulvestrant; HR = hazard ratio; LHRH = luteinising hormone-releasing hormone; n = number of patients; NE = not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.
© 2021 Pfizer Pte Ltd. All rights reserved.
The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.